Predicting response of bladder cancers to gemcitabine and carboplatin neoadjuvant chemotherapy through genome-wide gene expression profiling

Yoichiro Kato, Hitoshi Zembutsu, Ryo Takata, Fuyuki Miya, Tatsuhiko Tsunoda, Wataru Obara, Tomoaki Fujioka, Yusuke Nakamura

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)


Neoadjuvant chemotherapy with gemcitabine and carboplatin (GC) for invasive bladder cancer increases the chance of a radical response for a subset of patients, while other patients suffer from severe adverse drug reactions without any benefit. To establish a method for predicting the response to chemotherapy with GC, the expression profiles of biopsy samples from 37 advanced bladder cancers were analyzed using a microarray consisting of 38,500 genes or ESTs. Upon analysis of 9 'responder' and 9 'non-responder' tumors, 12 'predictive' genes were found to be significantly differentially expressed between the 'responder' and 'non-responder' groups, and a numerical prediction scoring system that clearly separated the responder group from the non-responder group was established. This system accurately predicted the drug responses of 18 of 19 additional test cases that were reserved from the original 37 cases. Moreover, a quantitative PCR-based prediction system was developed that may be feasible for routine clinical use, and the sensitivity of invasive bladder cancer to neoadjuvant chemotherapy with GC was able to be predicted by the expression patterns in this set of genes. Nearly 50% of patients treated with GC or methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) therapy have been reported to achieve complete or partial response to either of these therapies. When we applied this prediction system as well as the system for M-VAC, we expected that approximately 80% of the patients would achieve significant tumor shrinking (>60%) by selection of either the GC or M-VAC regimens. Our results suggest that the two prediction scoring systems lead to achievement of 'personalized therapy' for the treatment of invasive bladder cancer and should improve the quality of life for patients with this disease.

Original languageEnglish
Pages (from-to)47-56
Number of pages10
JournalExperimental and Therapeutic Medicine
Issue number1
Publication statusPublished - 2011 Jan
Externally publishedYes


  • Bladder cancer
  • Carboplatin
  • Gemcitabine
  • Gene expression profile
  • Microarray
  • Neoadjuvant chemotherapy
  • Prediction

ASJC Scopus subject areas

  • Immunology and Microbiology (miscellaneous)
  • Cancer Research


Dive into the research topics of 'Predicting response of bladder cancers to gemcitabine and carboplatin neoadjuvant chemotherapy through genome-wide gene expression profiling'. Together they form a unique fingerprint.

Cite this